You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Harvard Business School
Colorcon
Johnson and Johnson
Dow

Last Updated: February 26, 2024

CLINICAL TRIALS PROFILE FOR EXEMESTANE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Exemestane

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002777 ↗ Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast Cancer Completed European Organisation for Research and Treatment of Cancer - EORTC Phase 3 1996-05-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight cancer by blocking the uptake of estrogen. PURPOSE: Randomized phase II/III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women who have locally recurrent or metastatic breast cancer.
NCT00003418 ↗ Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer Unknown status European Organisation for Research and Treatment of Cancer - EORTC Phase 3 1998-02-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight breast cancer by blocking the uptake of estrogen. It is not yet known whether exemestane is more effective than tamoxifen in treating breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women with primary breast cancer who have already received 2-3 years of tamoxifen following surgery.
NCT00003418 ↗ Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer Unknown status UNICANCER Phase 3 1998-02-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight breast cancer by blocking the uptake of estrogen. It is not yet known whether exemestane is more effective than tamoxifen in treating breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women with primary breast cancer who have already received 2-3 years of tamoxifen following surgery.
NCT00003418 ↗ Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer Unknown status International Collaborative Cancer Group Phase 3 1998-02-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight breast cancer by blocking the uptake of estrogen. It is not yet known whether exemestane is more effective than tamoxifen in treating breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women with primary breast cancer who have already received 2-3 years of tamoxifen following surgery.
NCT00010010 ↗ Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer Completed National Cancer Institute (NCI) Phase 2 2000-06-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane plus goserelin may fight breast cancer by reducing the production of estrogen. PURPOSE: Phase II trial to study the effectiveness of exemestane and goserelin in treating premenopausal women who have metastatic breast cancer that has not responded to previous tamoxifen.
NCT00010010 ↗ Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer Completed New York University School of Medicine Phase 2 2000-06-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane plus goserelin may fight breast cancer by reducing the production of estrogen. PURPOSE: Phase II trial to study the effectiveness of exemestane and goserelin in treating premenopausal women who have metastatic breast cancer that has not responded to previous tamoxifen.
NCT00010010 ↗ Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer Completed NYU Langone Health Phase 2 2000-06-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane plus goserelin may fight breast cancer by reducing the production of estrogen. PURPOSE: Phase II trial to study the effectiveness of exemestane and goserelin in treating premenopausal women who have metastatic breast cancer that has not responded to previous tamoxifen.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Exemestane

Condition Name

Condition Name for Exemestane
Intervention Trials
Breast Cancer 107
Breast Neoplasms 31
Metastatic Breast Cancer 29
HER2/Neu Negative 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Exemestane
Intervention Trials
Breast Neoplasms 224
Neoplasms 10
Recurrence 6
Carcinoma 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Exemestane

Trials by Country

Trials by Country for Exemestane
Location Trials
United States 986
Italy 122
China 108
Canada 101
Spain 100
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Exemestane
Location Trials
Florida 43
Texas 43
California 43
New York 38
Tennessee 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Exemestane

Clinical Trial Phase

Clinical Trial Phase for Exemestane
Clinical Trial Phase Trials
Phase 4 9
Phase 3 61
Phase 2/Phase 3 2
[disabled in preview] 162
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Exemestane
Clinical Trial Phase Trials
Completed 97
Active, not recruiting 38
Recruiting 32
[disabled in preview] 78
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Exemestane

Sponsor Name

Sponsor Name for Exemestane
Sponsor Trials
Pfizer 40
National Cancer Institute (NCI) 33
Novartis Pharmaceuticals 19
[disabled in preview] 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Exemestane
Sponsor Trials
Other 240
Industry 157
NIH 36
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Boehringer Ingelheim
Merck
Mallinckrodt
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.